Choroidal Neovascularization, Age-related Macular Degeneration
Ophthalmology
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
GenentechRanibizumab 0.5 mg
Clinical Trials (1)
Total enrollment: 853 patients across 1 trials
An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO
Start: Apr 2005Est. completion: Sep 2008853 patients
N/ACompleted
Related Jobs in Ophthalmology
Lead Data Manager
Genomics
Remote
11h ago
Cleanroom and Laboratory Technician
SAB BIO
11h ago
Material Handler - 8 Hour Day Shift
Pfizer
United States - Kansas - McPherson
Yesterday
Senior Process Technician - Rotating 2nd Shift
Pfizer
United States - Massachusetts - Andover
Yesterday
$27 - $45/hr
Staff Equipment and Systems Engineer
Johnson & Johnson
Plymouth, Minnesota, United States of America
Yesterday
$94K - $152K/yr
APAC Regulatory Affairs Manager
Johnson & Johnson
Singapore, Singapore
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space